Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Moderna is investing more than $140 million to bring drug manufacturing to its Massachusetts campus, a move that it says will ...

Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its ...

Cambridge, USA-based mRNA vaccines company Moderna today announced the expansion of its US manufacturing capabilities with ...

Mixed options sentiment in Moderna (MRNA), with shares down 94c near $23.98. Options volume relatively light with 49k contracts traded and calls ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Moderna will invest $140 million in expanding its U.S. manufacturing capacity and onshoring its drug manufacturing to its existing facility in Norwood, Mass. The company said it will now operate full ...